Business · 04/01/2007Updated: 10/17/2026 · 1 min read

FDA Makes Available Summaries of Pediatric Study Reviews for AZOPT, BETAXON, and GLEEVEC

Summary

The FDA has released summaries of medical and clinical pharmacology reviews for pediatric studies submitted for AZOPT, BETAXON, and GLEEVEC, in compliance with the Best Pharmaceuticals for Children Act (BPCA)

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Add your company to Business Communicator

We monitor business sources and connect attention with companies, profiles and services available in Business Communicator.

Create a free company profile Explore businesses on Business Maps →

Create a free company profile →

Explore insights

Business insights →

Healthcare Business News Global Markets News Trade Regulation News Business Technology News Fintech for Business: Payments & Banking News Supply Chain News

Related business signals

Business · 10/9/2026

Center for Scientific Review Notice of Closed Meetings

The Center for Scientific Review has announced closed meetings for the following review groups: the Neurological Sciences A Study Section and the Neurological Sciences B Study Section.

Read summary →

Business · 10/5/2026

Center for Scientific Review Amends Meeting Notice

The Center for Scientific Review has updated its meeting notice, making the details publicly available.

Read summary →

Business · 9/28/2026

CDC Requests Public Comment on Proposed Colorectal Cancer Control Program Monitoring Activities

The Centers for Disease Control and Prevention (CDC) is seeking public input on a proposed data collection project, Colorectal Cancer Control Program (CRCCP) Monitoring Activities, as part of its effort to reduce public burden and maximize the utility of government information, in compliance with the Paperwork Reduction Act of 1995.

Read summary →

Business · 9/17/2026

FDA Grants Partial Exemption to Medical Devices

The FDA has finalized a rule exempting certain radiology computer-aided detection and diagnosis devices from premarket notification requirements, following a petition filed in 2025 and denied in 2026.

Read summary →

Business · 9/16/2026

Microbiology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Pathogen-Agnostic Sequencing

The Food and Drug Administration (FDA) announces a public advisory committee meeting of the Microbiology Devices Panel to discuss pathogen-agnostic sequencing for emergency preparedness and response efforts.

Read summary →

Business · 9/16/2026

Food and Drug Administration Announces Proposed Collection of Information for Reporting of Biological Product Deviations and Human Cells, Tissues, and Cellular and Tissue-Based Product Deviations in Manufacturing

The Food and Drug Administration (FDA) has submitted a proposed collection of information to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

Read summary →